Insight from a large real-world cohort of patients: does it confirm the results of the randomized trials?

Since the first transcatheter aortic valve replacement (TAVR) in 2002, the procedure has become a routine treatment for symptomatic severe aortic valve stenosis (AS) with centers performing more than 600 procedures a year (1).